Lp(a) and the EAS Risk Calculator: Bringing Hidden Cardiovascular Risk into Clinical View-Dr Suraj Patil

Background: Lp(a) as an Independent, Genetically-Determined CV Risk Factor

Cardiovascular risk assessment has conventionally relied on established factors — age, blood pressure, smoking status, diabetes, and standard lipid parameters. An important, largely inherited component of risk, however, can remain undetected by this framework: lipoprotein(a) [Lp(a)]. Predominantly genetically determined and generally stable across adulthood, elevated Lp(a) is independently associated with atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis. ^1,3

Contemporary guidelines have progressively incorporated Lp(a) into cardiovascular risk assessment. The 2026 ACC/AHA dyslipidaemia guideline recommends measuring Lp(a) at least once in all adults, designating ≥50 mg/dL (≥125 nmol/L) a risk-enhancing level.¹ The 2025 ESC/EAS focused update similarly recognises Lp(a) >50 mg/dL as a cardiovascular risk modifier of particular relevance in patients at moderate risk or near treatment-decision thresholds, emphasising that Lp(a)-associated risk rises continuously rather than at a single cut-off.² The 2024 NLA update stratifies risk further: <30 mg/dL as low, 30–50 mg/dL as intermediate, and ≥50 mg/dL as high.³

The clinical challenge extends beyond identifying an elevated Lp(a) value to understanding how it modifies an individual's overall cardiovascular risk — a gap the EAS Lp(a) Risk and Benefit Algorithm was developed to address by translating Lp(a) into quantified, patient-specific risk.

Patient Characteristics: Defining the Elevated Lp(a) Profile

The parameters used to illustrate the calculator's application are drawn from a subgroup within the Women's Health Study (WHS) with genetically elevated Lp(a) — identified via the LPA rs3798220 variant (heterozygous carriers, n=906).⁴ This subgroup was a median age of 52 years and BMI of 24.7 kg/m², with total cholesterol 215 mg/dL, LDL-C 126.5 mg/dL, and HDL-C 51.8 mg/dL — alongside low prevalence of hypertension, diabetes, current smoking, and family history of myocardial infarction.⁴ This should be viewed as a cohort-derived illustrative profile rather than an individual patient.

Quantifying the Risk: Lp(a) Levels and Cardiovascular Risk

Lp(a) concentrations varied markedly across the WHS cohort according to LPA rs3798220 genotype — the method used to classify elevated versus lower Lp(a) status in this analysis: a median of 10.0 mg/dL among those with lower Lp(a) (non-carriers), 79.5 mg/dL among those with elevated Lp(a) (heterozygous carriers), and 153.9 mg/dL among homozygous carriers (P<0.0001).⁴ This subgroup's median Lp(a) of 79.5 mg/dL falls firmly within the EAS-defined elevated-risk band (≥50 mg/dL) — nearly eight-fold higher than the lower-Lp(a) group — despite broadly similar conventional risk profiles across groups.

During 9.9 years of follow-up, participants with elevated Lp(a) assigned to placebo had an approximately two-fold higher risk of major cardiovascular events compared with placebo-treated participants with lower Lp(a) (age-adjusted HR 2.21, 95% CI 1.39–3.52).⁴

Making the Hidden Risk Visible: Applying the EAS Lp(a) Risk Calculator

Entering these WHS-derived parameters into the EAS Lp(a) Risk and Benefit Algorithm produces the following output, illustrating how a measured Lp(a) level of 79.5 mg/dL reshapes estimated lifetime cardiovascular risk (Figure 1):⁵

Figure 1. Estimated risk of myocardial infarction or stroke by age 80, without and with Lp(a) incorporated — EAS Lp(a) Risk and Benefit Algorithm applied to the WHS heterozygous-carrier profile (Lp(a) 79.5 mg/dL).⁵

As shown in Figure 1, the two risk trajectories diverge progressively with age, indicating that Lp(a)'s contribution to cardiovascular risk compounds over the lifespan rather than applying as a single, fixed adjustment.

The WHS Evidence: Aspirin's Cardiovascular Benefit at Higher Lp(a) Levels

The WHS genetic sub-study offers a rare randomised, controlled view of how aspirin's cardiovascular effect varies with Lp(a) status. Among participants with elevated Lp(a), aspirin was associated with a substantially lower incidence of major cardiovascular events versus placebo (age-adjusted HR 0.44, 95% CI 0.20–0.94, P=0.033). Among participants with lower Lp(a), no statistically significant benefit was observed (HR 0.91, 95% CI 0.77–1.08, P=0.30). The interaction between Lp(a) status and aspirin allocation was statistically significant (P=0.048), indicating that aspirin's cardiovascular benefit was meaningfully greater among those with elevated Lp(a).⁴

Figure 2. Cumulative incidence of myocardial infarction, ischemic stroke, or cardiovascular death by Lp(a) status and aspirin allocation. Lp(a) status was defined genetically via the LPA rs3798220 variant (elevated-Lp(a) group: heterozygous carriers, median Lp(a) 79.5 mg/dL; lower-Lp(a) group: non-carriers, median Lp(a) 10.0 mg/dL).

Simplified and redrawn for illustrative clarity from Chasman et al. 2009 (Figure 2A); curve shapes are approximate and not to original scale.⁴

Management: Targeting the Lp(a)-Driven Risk

Current management of elevated Lp(a) focuses primarily on reducing overall ASCVD risk through intensive control of modifiable risk factors, particularly LDL-C, blood pressure, glycaemia, smoking, and other established cardiovascular risk factors.¹Although several therapies specifically targeting Lp(a) production (e.g., pelacarsen, olpasiran) are in clinical development, dedicated Lp(a)-lowering agents have not yet become established, outcome-proven interventions in routine clinical practice.¹

The WHS findings provide a potential signal that aspirin's cardiovascular benefit may be greater in individuals with genetically elevated Lp(a). In this analysis, aspirin was associated with a lower incidence of major cardiovascular events compared with placebo among those with elevated Lp(a), an effect that was not observed among those with lower Lp(a).⁴

At this point, these findings suggest that Lp(a) level may help identify individuals in whom the potential cardiovascular benefit of aspirin deserves consideration. However, the evidence is based on subgroup/post-hoc genetic analyses and does not establish aspirin as an Lp(a)-specific treatment.^1,4

Any consideration of aspirin for primary prevention must therefore remain individualised, balancing potential cardiovascular benefit against gastrointestinal, intracranial, and other major bleeding risks. Elevated Lp(a) may inform this discussion, but it should not by itself determine aspirin use.¹

Clinical Takeaways

• Lp(a) can meaningfully refine ASCVD risk assessment. Elevated Lp(a) levels may identify an inherited CV risk component despite an otherwise unremarkable conventional

risk-factor profile.

• Translate the Lp(a) value into absolute risk. The EAS Lp(a) Risk and Benefit Algorithm can demonstrate the incremental impact of Lp(a) on estimated MI and stroke risk up to age 80, supporting more individualised risk assessment.

• Elevated Lp(a) should prompt optimisation of modifiable risk. Until outcome-proven Lp(a)-specific therapies become available, intensive LDL-C lowering and control of other established ASCVD risk factors remain the cornerstone of management.

• Aspirin's cardiovascular benefit may be greater at higher Lp(a) levels. WHS genetic analysis suggests a more pronounced aspirin effect among individuals with elevated Lp(a), but any decision to use aspirin in primary prevention should remain individualised, weighing overall cardiovascular benefit against bleeding risk.

Abbreviations

Lp(a), lipoprotein(a); ASCVD, atherosclerotic cardiovascular disease; WHS, Women's Health Study; RCT, randomised controlled trial; HR, hazard ratio; CI, confidence interval; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.